CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胶质母细胞瘤的免疫治疗：现状、挑战与未来展望
英文原题：Immunotherapy for glioblastoma: current state, challenges, and future perspectives.
查看英文原题
Immunotherapy for glioblastoma: current state, challenges, and future perspectives.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质母细胞瘤（GBM）是成人中一种侵袭性强且致命的脑肿瘤。标准治疗带来的临床获益极小，大多数GBM患者在治疗后出现肿瘤复发。近年来，在开发新型免疫疗法或其他能够克服许多晚期癌症免疫治疗耐药的治疗策略方面取得了重大进展。然而，由于独特的脑免疫特征、GBM细胞异质性以及免疫抑制性肿瘤微环境，免疫治疗在GBM中的获益有限。在这篇综述中，我们详细概述了当前的免疫治疗策略，并讨论了GBM中免疫治疗耐药的挑战和潜在分子机制。此外，我们深入讨论了能够克服GBM免疫治疗耐药的策略，这些策略很可能需要联合治疗。
展开英文摘要原文
Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human adults. The standard of care offers minimal clinical benefit, and most GBM patients experience tumor recurrence after treatment. In recent years, significant advancements have been made in the development of novel immunotherapies or other therapeutic strategies that can overcome immunotherapy resistance in many advanced cancers.
However, the benefit of immune-based treatments in GBM is limited because of the unique brain immune profiles, GBM cell heterogeneity, and immunosuppressive tumor microenvironment. In this review, we present a detailed overview of current immunotherapeutic strategies and discuss the challenges and potential molecular mechanisms underlying immunotherapy resistance in GBM.
Furthermore, we provide an in-depth discussion regarding the strategies that can overcome immunotherapy resistance in GBM, which will likely require combination therapies.
论文信息
- 作者
- Liu Y、Zhou F、Ali H、Lathia JD、Chen P
- 第一作者单位
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.United States
- 通讯作者单位
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA. CHENP6@ccf.org.United States
- 文献类型
- 综述 · 非美国政府资助研究 · 美国政府（非公共卫生署）资助研究 · 美国 NIH 资助研究
- 期刊
- Cellular & molecular immunology2024 Dec
- 原文标识
- PubMed 39406966 · DOI 10.1038/s41423-024-01226-x
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →